

Indication

COMIRNATY is approved for use to prevent COVID-19 in individuals who are 65 years of age and older, or 5 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.

Selected Safety Information

Do not administer COMIRNATY to individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of COMIRNATY or to individuals who had a severe allergic reaction (e.g., anaphylaxis) following a previous dose of a Pfizer-BioNTech COVID-19 vaccine.



Cost and coverage

COMIRNATY may be available at no cost. It may be made available by certain insurance plans in accordance with the Inflation Reduction Act.^{1*}

Coding for COMIRNATY

The information provided in this document is not intended to be conclusive, exhaustive, or to replace the guidance of a qualified professional advisor. This information is current as of June 2026 and is compiled from sources believed to be accurate, but Pfizer makes no representation as to accuracy. Coding and coverage policies change periodically and often without notice, so it is important to regularly check with each payer as to payer-specific requirements. HCPs are solely responsible for determining coverage and reimbursement parameters and appropriate coding for the treatment of their patients. Use of this information does not guarantee payment, coverage, or reimbursement for COMIRNATY or that payment received will cover costs.

CPT® codes for COMIRNATY—see complete indication on page 4 ²	
Eligible patients 12 years and older	91320 – SARS-CoV-2 vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use
Eligible patients 5–11 years old	91319 – SARS-CoV-2 vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use

CPT is a registered trademark of the American Medical Association.
CPT, Current Procedural Terminology; HCP, healthcare professional; LNP, lipid-based nanoparticle; mRNA, messenger ribonucleic acid.
^{*}This information is provided for informational purposes only. Accurate completion of reimbursement or coverage-related documentation is the responsibility of the healthcare provider and patient. Pfizer and its agents make no guarantee regarding reimbursement for any service or item. Certain vaccines may be covered or available at lower out-of-pocket costs in Medicare Part D, Medicaid, the Children’s Health Insurance Program, or other consumer plans through the Inflation Reduction Act. Coverage may vary based on the vaccine and the insurance plan. For more information, visit [cms.gov](https://www.cms.gov).

Please see additional Important Safety Information on following pages.
Please click for COMIRNATY Full [Prescribing Information](#) and [Patient Information](#).

Coding for COVID-19 vaccine administration

CPT code for the administration of any COVID-19 vaccine²

Eligible patients* **90480** – For the administration of any COVID-19 vaccine

Modifier when billing a visit and vaccine administration^{3,4}

When the visit is significant and separate from the vaccination **Add modifier -25 to the visit code** – Significant, separately identifiable evaluation and management service by the same physician or other qualified HCP on the same day of the procedure or other service

Modifier when billing CPT 90480 and CPT 90471[†] at the same visit⁴

When a COVID-19 vaccine and another vaccine are administered **Add modifier -59 to CPT 90480** – Distinct Procedural Service

Diagnosis codes (ICD-10-CM codes)

Accurate ICD-10-CM coding is important for private insurance companies, Medicare, and Medicaid. The Z23 code in the ICD-10-CM system is the primary code for vaccine encounters related to preventive care. When applicable, in addition to the Z23 code, consider adding the patient-specific ICD-10 code that describes the condition that puts the patient at increased risk for severe COVID-19.

ICD-10-CM codes for immunization⁵

Eligible patients	Z23 (encounter for immunization)
Patients at increased risk for severe COVID-19	Patient-specific ICD-10 code that describes the patient's condition

Note: Due to the indication for patients who are between the ages of 5 through 64 years, some payers may require an additional ICD-10-CM code that describes the patient's condition to show that they are at an increased risk for severe COVID-19.

ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification.

*Medicaid plans often modify coding for administration of vaccines supplied by the Vaccines for Children (VFC) Program. Review your state's coding rules.⁶

[†]CPT 90471, immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid).⁷

Important Safety Information (continued)

Management of Acute Allergic Reactions

Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of COMIRNATY.

Myocarditis and Pericarditis

Postmarketing data from use of authorized or approved mRNA COVID-19 vaccines, including COMIRNATY, have demonstrated increased risks of myocarditis and pericarditis, with onset of symptoms typically in the first week following vaccination. The observed risk has been highest in males 12 years through 24 years of age.

Syncope

Syncope (fainting) may occur in association with administration of injectable vaccines, including COMIRNATY. Procedures should be in place to avoid injury from fainting.

Please see additional Important Safety Information on following pages.

Please click for COMIRNATY Full [Prescribing Information](#) and [Patient Information](#).

NDCs and registry codes

Some payers require an NDC in addition to the CPT code for the product—make sure to use the appropriate 11-digit NDCs noted below.

COMIRNATY NDCs ⁸		Billing format
2026-2027 Formula 12 years of age and older who are at high risk for severe COVID-19	00069-2631-10 – Carton of 10 single-dose prefilled syringes unit of sale	N400069263110 ML0.3
	00069-2631-01 – Single-dose prefilled syringe unit of use	N400069263101 ML0.3
2026-2027 Formula 5 through 11 years of age who are at high risk for severe COVID-19	00069-2609-10 – Carton of 10 single-dose vials unit of sale	N400069260910 ML0.3
	00069-2609-01 – Single-dose vial unit of use	N400069260901 ML0.3

Immunization registries rely on CVX and MVX codes for accurate data entry. The CVX code specifies the vaccine product administered. The MVX code identifies its manufacturer. When these codes are combined, they identify the exact trade-named vaccine used.

COMIRNATY registry codes ^{9,10}	
MVX	PFR
CVX	309 – 2026-2027 Formula 12 years of age and older
	310 – 2026-2027 Formula 5 through 11 years of age

CVX, vaccine administered; MVX, manufacturer of vaccine; NDC, National Drug Code.

Important Safety Information (continued)

Altered Immunocompetence

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to COMIRNATY.

Limitation of Vaccine Effectiveness

COMIRNATY may not protect all vaccine recipients.

Adverse Reactions

Most commonly reported adverse reactions after a dose:

- **12 years of age and older** ($\geq 10\%$) were pain at the injection site (up to 90.5%), fatigue (up to 77.5%), headache (up to 75.5%), chills (up to 49.2%), muscle pain (up to 45.5%), joint pain (up to 27.5%), fever (up to 24.3%), injection site swelling (up to 11.8%), and injection site redness (up to 10.4%).
- **5 years through 11 years of age** ($\geq 5\%$) were pain at the injection site (up to 83.8%), fatigue (up to 51.9%), headache (up to 38.4%), injection site redness (up to 25.9%), injection site swelling (up to 20%), muscle pain (up to 18.1%), chills (up to 13.3%), fever (up to 7.8%), and joint pain (up to 7.6%).

Please see additional Important Safety Information on page 4.

Please click for COMIRNATY Full [Prescribing Information](#) and [Patient Information](#).

Important Safety Information and Indication



Important Safety Information

Do not administer COMIRNATY® (COVID-19 Vaccine, mRNA) to individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of COMIRNATY or to individuals who had a severe allergic reaction (e.g., anaphylaxis) following a previous dose of a Pfizer-BioNTech COVID-19 vaccine.

Management of Acute Allergic Reactions

Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of COMIRNATY.

Myocarditis and Pericarditis

Postmarketing data from use of authorized or approved mRNA COVID-19 vaccines, including COMIRNATY, have demonstrated increased risks of myocarditis and pericarditis, with onset of symptoms typically in the first week following vaccination. The observed risk has been highest in males 12 years through 24 years of age.

Syncope

Syncope (fainting) may occur in association with administration of injectable vaccines, including COMIRNATY. Procedures should be in place to avoid injury from fainting.

Altered Immunocompetence

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to COMIRNATY.

Limitation of Vaccine Effectiveness

COMIRNATY may not protect all vaccine recipients.

Adverse Reactions

Most commonly reported adverse reactions after a dose:

- **12 years of age and older** ($\geq 10\%$) were pain at the injection site (up to 90.5%), fatigue (up to 77.5%), headache (up to 75.5%), chills (up to 49.2%), muscle pain (up to 45.5%), joint pain (up to 27.5%), fever (up to 24.3%), injection site swelling (up to 11.8%), and injection site redness (up to 10.4%).
- **5 years through 11 years of age** ($\geq 5\%$) were pain at the injection site (up to 83.8%), fatigue (up to 51.9%), headache (up to 38.4%), injection site redness (up to 25.9%), injection site swelling (up to 20%), muscle pain (up to 18.1%), chills (up to 13.3%), fever (up to 7.8%), and joint pain (up to 7.6%).

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or <https://www.pfizersafetyreporting.com> or VAERS at 1-800-822-7967 or <https://vaers.hhs.gov>

Indication

COMIRNATY is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

COMIRNATY is approved for use in individuals who are:

- 65 years of age and older, or
- 5 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.

Please click for COMIRNATY Full Prescribing Information and Patient Information.

References: 1. Data on File. Pfizer Inc.; February 2026. 2. American Medical Association. Big changes will streamline CPT coding for immunization. Published January 5, 2024. Accessed March 24, 2026. <https://www.ama-assn.org/practice-management/cpt/big-changes-will-streamline-cpt-coding-immunization> 3. American Medical Association. Reporting CPT modifier 25. Accessed March 24, 2026. <https://www.ama-assn.org/system/files/reporting-cpt-modifier-25.pdf> 4. Centers for Medicare and Medicaid Services. Chapter 1 general correct coding policies for Medicare national correct coding initiative policy manual. Updated February 28, 2025. Accessed March 24, 2026. <https://www.cms.gov/files/document/01-chapter1-nccci-medicare-policy-manual-2025finalcleanpdf.pdf> 5. American Academy of Professional Coders. ICD-10-CM code for encounter for immunization Z23. Accessed March 24, 2026. <https://www.aapc.com/codes/icd-10-codes/Z23> 6. New York State Department of Health. Medicaid update. Published October 2024. Accessed March 24, 2026. https://www.health.ny.gov/health_care/medicaid/program/update/2024/docs/mu_no11_oct24.pdf 7. American Medical Association. CPT category I new immunization vaccine codes (including incorporation of ACIP abbreviations listing) long descriptors. Updated August 2, 2023. Accessed March 24, 2026. <https://www.nvic.org/NVIC/media/Assets/PDFs/AMA-July-2023-CPT-Codes-RSV.pdf> 8. COMIRNATY. Prescribing information. BioNTech Manufacturing GmbH and Pfizer Inc.; 2025. 9. Centers for Disease Control and Prevention. HL7 standard code set CVX. Accessed March 24, 2026. <https://www.2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cvx> 10. Centers for Disease Control and Prevention. HL7 standard code set MVX. Accessed March 24, 2026. <https://www.2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=mvx>